Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Immunotherapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squam...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E., Chow, Laura Q. M., Burgio, Marco Angelo, de Castro Carpeno, Javier, Pluzanski, Adam, Arrieta, Oscar, Frontera, Osvaldo Arén, Chiari, Rita, Butts, Charles, Wójcik-Tomaszewska, Joanna, Coudert, Bruno, Garassino, Marina Chiara, Ready, Neal, Felip, Enriqueta, García, Miriam Alonso, Waterhouse, David, Domine, Manuel, Barlesi, Fabrice, Antonia, Scott, Wohlleber, Markus, Gerber, David E., Czyzewicz, Grzegorz, Spigel, David R., Crino, Lucio, Eberhardt, Wilfried Enst Erich, Li, Ang, Marimuthu, Sathiya, Brahmer, Julie
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078445/
https://ncbi.nlm.nih.gov/pubmed/33449799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01605
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados